Definium director exercises options for 1,086 shares
Definium Therapeutics, Inc. (DFTX) director Carol A. Vallone reported exercising stock options on September 18, 2026 to acquire 1,086 Common Shares at an exercise price of $35.52 per share.
Rhea-AI Filing Summary
Definium Therapeutics, Inc. (DFTX) director Carol A. Vallone reported exercising stock options on September 18, 2026 to acquire 1,086 Common Shares at an exercise price of $35.52 per share. Following the transaction, she directly holds 22,296 Common Shares, and the exercised option position is reduced to zero.
Positive
- None.
Negative
- None.
Insider Trade Summary
1,086 shares exercised/converted
Exercise
2 txns
Insider
Vallone Carol A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 1,086 | $0.00 | $0.00 |
| Exercise | Common Shares | 1,086 | $35.52 | $39K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Shares — 22,296 shares (Direct)
Key Figures
Shares acquired via option exercise: 1,086 shares
Exercise price: $35.52 per share
Common Shares held after transaction: 22,296 shares
+3 more
6 metrics
Shares acquired via option exercise
1,086 shares
Common Shares received on option exercise dated September 18, 2026
Exercise price
$35.52 per share
Exercise price of the Stock Option (Right to Buy) for 1,086 shares
Common Shares held after transaction
22,296 shares
Directly held Common Shares following the September 18, 2026 exercise
Derivative shares exercised
1,086 derivative shares
Stock Option (Right to Buy) converted into Common Shares on September 18, 2026
Option expiration date
September 29, 2026
Original expiration date of the exercised stock option
Derivative shares remaining from this option
0 shares
Total Stock Option (Right to Buy) shares following the exercise
Key Terms
Stock Option (Right to Buy), Common Shares, derivative security
3 terms
Stock Option (Right to Buy) financial
"The security title is listed as Stock Option (Right to Buy) for 1,086 shares"
derivative security financial
"The transaction code description states Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DFTX director Carol A. Vallone report?
Carol A. Vallone reported exercising a stock option for 1,086 Common Shares of Definium Therapeutics, Inc. on September 18, 2026, converting a derivative position into directly held common shares.
What are Carol A. Vallone’s holdings in DFTX after this Form 4 transaction?
After the option exercise, Carol A. Vallone directly holds 22,296 Common Shares of Definium Therapeutics, Inc., according to the post-transaction share balance reported on the Form 4.
What happened to the stock option position reported by Carol A. Vallone for DFTX?
The reported Stock Option (Right to Buy) for 1,086 shares with an exercise price of $35.52 and an expiration date of September 29, 2026 was exercised in full, leaving 0 derivative shares from that option grant.
Was Carol A. Vallone’s DFTX option exercise under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not affirmed (the box is unchecked), and there are no footnotes indicating that the September 18, 2026 option exercise was made pursuant to a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
